How Does Stelara Work? Mechanism of Action Explained in Plain English

If you've been prescribed Stelara, you might be wondering: what exactly is this medication doing inside my body? Unlike simple painkillers or antibiotics, biologic medications like Stelara work at the molecular level — targeting very specific proteins that drive inflammation. Understanding how Stelara works can help you feel more confident about your treatment and better equipped to have conversations with your doctor.

First: What Is Causing the Inflammation?

In conditions like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, the immune system is overactive. It mistakenly identifies parts of the skin or gut as threats and triggers an inflammatory response to attack them. This leads to the symptoms you experience — red, scaly skin in psoriasis; joint pain in psoriatic arthritis; abdominal pain and diarrhea in IBD.

At the heart of this overactive immune response are signaling proteins called cytokines. Two cytokines play a particularly important role in these conditions: interleukin-12 (IL-12) and interleukin-23 (IL-23).

What Are IL-12 and IL-23?

IL-12 and IL-23 are proteins produced by certain immune cells. Think of them as chemical messengers that tell other immune cells to become more active and inflammatory. Specifically:

IL-12 activates a type of immune cell called Th1 cells, which drive inflammation and immune responses against pathogens — but in autoimmune disease, they turn against the body's own tissues.

IL-23 activates Th17 cells, which are strongly implicated in the inflammation seen in psoriasis, psoriatic arthritis, and IBD. IL-23 also helps sustain the inflammatory environment by supporting the survival and activity of Th17 cells.

Both IL-12 and IL-23 share a common protein subunit called p40. This is the key piece of the puzzle that makes Stelara unique.

How Does Stelara Block IL-12 and IL-23?

Stelara (ustekinumab) is a fully human monoclonal antibody — a precisely engineered protein designed to bind specifically to the p40 subunit shared by both IL-12 and IL-23. When ustekinumab attaches to p40, it physically blocks IL-12 and IL-23 from binding to their receptors on immune cell surfaces.

It's like putting a lock on the doorbell. If IL-12 and IL-23 can't ring the doorbell (bind to their receptors), they can't tell the immune cells inside to start causing inflammation. This breaks the signaling chain that leads to symptoms.

What Makes Stelara Different from Other Biologics?

Stelara's dual blockade of both IL-12 and IL-23 through the shared p40 subunit was considered uniquely valuable when it launched. Other biologics target different parts of the inflammatory cascade:

TNF inhibitors (Humira, Remicade, Enbrel): Block tumor necrosis factor (TNF), a different inflammatory cytokine. Broadly suppress inflammation but through a different pathway.

IL-17 inhibitors (Cosentyx, Taltz): Block IL-17A, a downstream cytokine that IL-23 activates. More targeted to Th17 pathway effects.

IL-23 selective inhibitors (Skyrizi, Tremfya): Block only IL-23 (not IL-12). Newer generation biologics that specifically target IL-23's unique p19 subunit, leaving IL-12 activity intact.

Stelara's mechanism is considered highly targeted compared to broad immunosuppressants (like methotrexate or steroids), while also addressing the dual IL-12/IL-23 pathway that contributes to disease across multiple conditions.

How Quickly Does Stelara's Mechanism Take Effect?

After your first injection, Stelara begins binding to IL-12 and IL-23 in your bloodstream right away. But the downstream effects — reduced immune cell activation, lower inflammation, tissue healing — take weeks to fully develop. Most patients see initial improvement in psoriasis plaques within 4-8 weeks, with significant clearing often by Week 12. IBD patients typically see a response to the IV induction dose at 8-12 weeks.

Why Does Stelara Stay in the Body So Long?

Stelara is a large protein (1,326 amino acids, molecular mass approximately 148,000-149,000 Daltons). Like other antibodies in the body, ustekinumab is not quickly broken down. It circulates in the bloodstream for weeks, which is why dosing is so infrequent — every 12 weeks for psoriasis and psoriatic arthritis, and every 8 weeks for IBD maintenance.

Unlike standard drugs that are processed by the liver and kidneys, ustekinumab is broken down by the body's natural protein-digesting enzymes — the same way the body handles its own antibodies. This is why standard drug metabolism interactions are minimal.

For a complete overview of Stelara including dosing, side effects, and cost in 2026, see: What Is Stelara? Uses, Dosage, and What You Need to Know in 2026